Tag: young adults

The Phony War on American Culture

Tina Marie (Ms. Cat)

The Phony War on American Culture

Consider how gender is one focus of their culture war campaign. Transgender people hardly affect our personal lives, despite the Republican campaigns to make it a voting issue. In America, only 1.3 million adults and 300,000 children identify as transgender out of a population of 332 million. Only 36 transgender athletes compete in college sports that include over half a million participants. Yet the Republican legislature in Kansas recently banned transgender girls from female high school sports, despite having only three transgender girls out of 41,00 competing in the state. Indeed, they should be respected and accommodated in some way. Yet, GOP legislators are considering a flood of bills to restrict transgender behavior, flooding email boxes with requests for donations, blasting isolated events on Fox News, and making them campaign issues.

Pfizer’s anti-COVID pill Paxlovid shows no benefit for younger adults

Tina Marie (Ms. Cat)

Pfizer’s anti-COVID pill Paxlovid shows no benefit for younger adults

The report’s authors found that Pfizer’s antiviral medication Paxlovid offered little to no benefit for younger adults. However, it did reduce the risk of hospitalization for high-risk seniors. Notably, supplementary material from the original study of Paxlovid in high-risk non-hospitalized adults with COVID-19 during the Delta wave had demonstrated benefits in those younger than 65, albeit the difference compared to the placebo was much less than in those 65 and older.

…

Among those over 65, there was a 73 percent decrease in the hospitalization rate and a 79 percent reduction in the risk of death. However, patients between the ages of 40 and 65 saw no benefit in taking the antiviral medication in either category, regardless of previous immunity status.

…

Another critical study from Hong Kong published in Lancet Infectious Diseases on the same day as the Israeli study but which went unmentioned in the press offered further evidence of Paxlovid’s limited therapeutic role. The authors reviewed their clinical experience with Paxlovid and Lagevrio, Merck’s antiviral pill, Molnupiravir, in hospitalized patients. They compared them to hospitalized patients who did not receive those medications during the horrific wave of infections that slammed into the semi-autonomous region in February and March.

…

The mortality risk reduction for Lagevrio was 52 percent, and for Paxlovid it was 66 percent. Those receiving antivirals had a lower risk of their disease progressing, but the drugs did not significantly impact their need for mechanical ventilation or ICU admission. The patients in the study averaged in age from mid-70s to early 80s.

…

Given the results of these studies, it bears mentioning that the Centers for Disease Control and Prevention (CDC) has recently estimated that approximately 95 percent of Americans aged 16 and older have some level of immunity against COVID-19.